caa a22 4500 463186842 CHVBK 20180406164856.0 cr unu---uuuuu 170326e20070801xx s 000 0 eng 10.1007/s00726-007-0516-1 doi (NATIONALLICENCE)springer-10.1007/s00726-007-0516-1 Tissue transglutaminase in tumour progression: friend or foe? [Elektronische Daten] [P. Kotsakis, M. Griffin] Summary.: Basic biological processes in which tissue transglutaminase (TG2, tTG) is thought to be important including apoptosis, cell adhesion and migration, ECM homeostasis and angiogenesis are key stages in the multistage tumour progression cascade. Studies undertaken with primary tumours and experimental models suggest that TG2 expression and activity in the tumour body and surrounding matrix generally decreases with tumour progression, favouring matrix destabilisation, but supporting angiogenesis and tumour invasion. In contrast, in the secondary metastatic tumour TG2 is often highly expressed whereby its potential roles in cell survival both at the intra- and extracellular level become important. In the following review the underlying molecular basis for the selection of these different phenotypes in tumour types and the anomaly for the requirement of TG2 is discussed in relation to the complex events of tumour progression. Springer-Verlag, 2007 Keywords: Enzyme - Tissue transglutaminase - Tumour growth - Angiogenesis - Extracellular matrix - Review nationallicence bFGF : basic fibroblast growth factor nationallicence EC : endothelial cell nationallicence ECM : extracellular matrix nationallicence EGF : endothelial growth factor nationallicence FAK : focal adhesion kinase nationallicence LTBP : latent transforming growth factor-β binding protein nationallicence MMP : matrix metalloproteinase nationallicence NF-kappa B : nuclear factor-kappa B nationallicence NO : nitric oxide nationallicence TG2 : tissue transglutaminase nationallicence TGF-β : transforming growth factor β nationallicence TIMP : tissue inhibitor of matrix metalloproteinases nationallicence uPA : urokinase plasminogen activator nationallicence uPARAP : urokinase plasminogen activator receptor associated protein nationallicence VEGF : vascular endothelial growth factor nationallicence Kotsakis P. Unilever R&D Port Sunlight, Bebington, Wirral, U.K. aut Griffin M. School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham, U.K. aut Amino Acids Springer-Verlag 33/2(2007-08-01), 373-384 0939-4451 33:2<373 2007 33 726 https://doi.org/10.1007/s00726-007-0516-1 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00726-007-0516-1 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Kotsakis P. Unilever R&D Port Sunlight, Bebington, Wirral, U.K aut NATIONALLICENCE 700 1- Griffin M. School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham, U.K aut NATIONALLICENCE 773 0- Amino Acids Springer-Verlag 33/2(2007-08-01), 373-384 0939-4451 33:2<373 2007 33 726 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer